InvestorsHub Logo
Followers 0
Posts 7
Boards Moderated 0
Alias Born 03/12/2019

Re: Lazarus post# 5564

Monday, 09/16/2019 11:56:02 AM

Monday, September 16, 2019 11:56:02 AM

Post# of 5675
Hi. Just wanted to clear up a few things.

The gene therapy article that was posted earlier is for NPC type A. It's a completely different disease. Advances for Type A mean pretty much nothing for NPC1. The only thing these diseases share is a name. There are people working on gene therapy for NPC1, but as far as I know, that could be a decade or more away. Even then, there is no evidence that gene therapy will "cure". It is more likely to result in a less aggressive form of NPC1.

The fact that the Hempel twins passed away does not reflect badly on CTDH. My understanding is that the twins were fairly progressed before they received treatment. Cyclodextrin is not a cure and has never claimed to be a cure. It slows the progression of the disease, that's all. I see kids on cycloodextrin die all the time. This is not unexpected or shocking. The Hempels are true pioneers in the NPC1 community. They did a great deal for the community. We are all heartbroken by the passing of the twins.

There was recent post about CTD appearing on TV. If you do any research at all, it is clear that that Red Chip is a public relations/investor relations firm.
https://www.redchip.com
Why CEO's Hire RedChip
https://www.redchip.com/corporate/why_redchip

Best I can tell, the "TV interview" was a paid for infomercial, to attract potential investors. Nothing wrong with that. They should be doing every thing they can to attract investors. However, it does seem a bit misleading.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTH News